ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160824005294/en/
“Todd is a seasoned leader with significant financial and operational
experience in the biopharmaceutical industry,” said
Mr. Young joins ACADIA from
Early in his career, Mr. Young practiced as a tax attorney at a major
law firm. Mr. Young earned his Bachelor of Arts degree in Economics from
“I am thrilled to join ACADIA,” said
About
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.com to which we regularly post copies of our press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include but are
not limited to statements related to ACADIA’s plans to bring NUPLAZID™
(pimavanserin) to patients in need, to maximize opportunities for
pimavanserin, and to build a leading CNS company and shareholder value,
as well as potential contributions of Mr. Young as ACADIA’s Executive
Vice President, Chief Financial Officer. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and in
collaborations with others, and the fact that past results of clinical
trials may not be indicative of future trial results. For a discussion
of these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20160824005294/en/
Source:
Investor Contact:
ACADIA Pharmaceuticals Inc.
Lisa
Barthelemy, Investor Relations
(858) 558-2871
ir@acadia-pharm.com
or
Media
Contact:
Taft and Partners
Ted Deutsch
(609)
578-8765
ted@taftandpartners.com